valproic acid has been researched along with Dysmyelopoietic Syndromes in 41 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in high-risk myelodysplastic syndromes (MDS) cases with unfavorable prognosis." | 9.15 | Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. ( Chiarini, F; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Martelli, AM; Martinelli, G; Mongiorgi, S; Paolini, S; Ramazzotti, G, 2011) |
| "We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients." | 9.12 | Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. ( Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H, 2006) |
| " In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML." | 6.73 | Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. ( Hallman, H; Honkanen, T; Juvonen, E; Kauppila, M; Koistinen, P; Kutila, A; Mikkola, M; Nyländen, P; Poikonen, E; Rauhala, A; Savolainen, ER; Siitonen, T; Sinisalo, M; Suominen, M; Terävä, V; Timonen, T, 2007) |
| "Valproic acid (VPA) has been shown to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid (ATRA) in the differentiation induction of acute myelogenous leukemia (AML) blasts in vitro." | 6.71 | Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. ( Aivado, M; Bernhardt, A; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Kuendgen, A; Strupp, C, 2004) |
| "Valproic acid (VPA) is an effective first-line anticonvulsant that is associated with several side effects including bone marrow suppression and subsequent cytopenia." | 5.72 | Valproic Acid Induced Thrombocytopenia and Dysmegakaryopoiesis in a Pediatric Patient. ( Akgun, Y; Baykara, Y; Langlie, J; Poveda, J; Van Truong, L, 2022) |
| "The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in high-risk myelodysplastic syndromes (MDS) cases with unfavorable prognosis." | 5.15 | Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. ( Chiarini, F; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Martelli, AM; Martinelli, G; Mongiorgi, S; Paolini, S; Ramazzotti, G, 2011) |
| "We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients." | 5.12 | Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. ( Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H, 2006) |
| "Two demethylating agents are approved in myelodysplastic syndromes (MDS): 5-azacitidine and 5-aza-2'-deoxycitidine (decitabine)." | 4.84 | Demethylating agents in myeloid malignancies. ( Garcia-Manero, G, 2008) |
| " We conclude that VPA is a safe and effective treatment option for MDS and AML patients, particularly when used in conjunction with all-trans retinoic acid, DNA-hypomethylating drugs, and hydralazine." | 3.01 | Efficacy and Safety of Valproic Acid in Myelodysplastic Syndrome and Acute Myeloid Leukemia; a Narrative Review. ( Mahdiani, S; Mohammadpour, AH; Omidkhoda, N; Rahimi, H; Samadi, S, 2023) |
| "The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day." | 2.76 | Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. ( Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S, 2011) |
| "To evaluate the efficacy and adverse effect of valproic acid (VPA) in combination with low dose chemotherapy on intermediate and high-risk myelodysplastic syndrome." | 2.76 | [The efficacy and safety of valproic acid in combination with low dose chemotherapy on intermediate and high-risk myelodysplastic syndrome]. ( Ge, GM; Han, XL; He, LS; Huang, Y; Wu, S; Yan, YP; Zhang, QY, 2011) |
| " In conclusion, the combination studied is safe and has significant clinical activity." | 2.73 | Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. ( Cortes, J; Estey, EH; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Issa, JP; Kantarjian, HM; Ouzounian, S; Pierce, S; Quezada, A; Ravandi, F; Soriano, AO; Wierda, WG; Yang, H, 2007) |
| " In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML." | 2.73 | Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. ( Hallman, H; Honkanen, T; Juvonen, E; Kauppila, M; Koistinen, P; Kutila, A; Mikkola, M; Nyländen, P; Poikonen, E; Rauhala, A; Savolainen, ER; Siitonen, T; Sinisalo, M; Suominen, M; Terävä, V; Timonen, T, 2007) |
| "Valproic acid (VPA) has been shown to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid (ATRA) in the differentiation induction of acute myelogenous leukemia (AML) blasts in vitro." | 2.71 | Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. ( Aivado, M; Bernhardt, A; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Kuendgen, A; Strupp, C, 2004) |
| " For patients with high-risk MDS, VPA may be combined with chemotherapy or demethylating drugs." | 2.71 | Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. ( Fox, F; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Knipp, S; Kuendgen, A; Steidl, C; Strupp, C, 2005) |
| "Valproic acid (VPA) is an HDACi and has been known as anti-epileptic agent for many years." | 2.44 | Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. ( Bellos, F; Mahlknecht, U, 2008) |
| " Recent clinical trials investigate new dosing schedules, routes of administration, and combination regimens." | 2.44 | Current status of epigenetic treatment in myelodysplastic syndromes. ( Kuendgen, A; Lübbert, M, 2008) |
| "Valproic acid (VPA) is an effective first-line anticonvulsant that is associated with several side effects including bone marrow suppression and subsequent cytopenia." | 1.72 | Valproic Acid Induced Thrombocytopenia and Dysmegakaryopoiesis in a Pediatric Patient. ( Akgun, Y; Baykara, Y; Langlie, J; Poveda, J; Van Truong, L, 2022) |
| "Hydralazine was dosed according to the acetylation genotype of patients (slow acetylators 83 mg daily; fast acetylators 182 mg daily), and valproate was dosed at 30 mg/kg/day." | 1.46 | Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). ( Burgos, S; Candelaria, M; Dueñas-Gonzalez, A; Espinoza, R; Ponce, M, 2017) |
| "Co-treatment with VPA and bortezomib on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cell lines resulted in marked inhibition of proliferation and induction of apoptosis, including a striking increase in mitochondrial injury, caspase cascade activation, and altered expression of Bcl-2 family proteins." | 1.37 | Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. ( Chen, L; Li, JM; Shen, ZX; Wang, AH; Wei, L; Wu, WL; Zhao, SQ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.32) | 18.2507 |
| 2000's | 20 (48.78) | 29.6817 |
| 2010's | 15 (36.59) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, AH | 1 |
| Seymour, JF | 1 |
| Akgun, Y | 1 |
| Baykara, Y | 1 |
| Langlie, J | 1 |
| Van Truong, L | 1 |
| Poveda, J | 1 |
| Omidkhoda, N | 1 |
| Mahdiani, S | 1 |
| Samadi, S | 1 |
| Rahimi, H | 1 |
| Mohammadpour, AH | 1 |
| Park, S | 1 |
| Hamel, JF | 1 |
| Toma, A | 1 |
| Kelaidi, C | 1 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 3 |
| Sekeres, MA | 2 |
| Balleari, E | 1 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 1 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Guerci-Bresler, A | 1 |
| Bordessoule, D | 1 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 1 |
| Rose, C | 1 |
| Vey, N | 1 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 4 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Fenaux, P | 2 |
| Candelaria, M | 2 |
| Burgos, S | 1 |
| Ponce, M | 1 |
| Espinoza, R | 1 |
| Dueñas-Gonzalez, A | 2 |
| Lübbert, M | 2 |
| Kuendgen, A | 4 |
| Issa, JP | 3 |
| Garcia-Manero, G | 5 |
| Huang, X | 1 |
| Cortes, J | 3 |
| Ravandi, F | 3 |
| Jabbour, E | 3 |
| Borthakur, G | 1 |
| Brandt, M | 1 |
| Pierce, S | 2 |
| Kantarjian, HM | 5 |
| Ornstein, MC | 1 |
| Mukherjee, S | 1 |
| Jacob, L | 1 |
| Uvarova, M | 1 |
| Boulet, S | 1 |
| Begaj, I | 1 |
| Chevret, S | 2 |
| Yu, C | 1 |
| Chen, BA | 4 |
| Gao, C | 4 |
| Ding, JH | 3 |
| Xia, GH | 4 |
| Shao, ZY | 4 |
| Gao, F | 2 |
| Sun, YY | 2 |
| Cheng, J | 2 |
| Zhao, G | 3 |
| Wang, J | 3 |
| Song, HH | 2 |
| Ma, Y | 1 |
| Bao, W | 2 |
| Bellos, F | 1 |
| Mahlknecht, U | 1 |
| Nachtkamp, K | 1 |
| Kündgen, A | 1 |
| Strupp, C | 3 |
| Giagounidis, A | 1 |
| Kobbe, G | 1 |
| Gattermann, N | 3 |
| Haas, R | 3 |
| Voso, MT | 1 |
| Finelli, C | 2 |
| Musto, P | 1 |
| Pogliani, E | 1 |
| Angelucci, E | 1 |
| Fioritoni, G | 1 |
| Alimena, G | 1 |
| Maurillo, L | 1 |
| Cortelezzi, A | 1 |
| Buccisano, F | 1 |
| Gobbi, M | 1 |
| Borin, L | 1 |
| Di Tucci, A | 1 |
| Zini, G | 1 |
| Petti, MC | 1 |
| Martinelli, G | 2 |
| Fabiani, E | 1 |
| Fazi, P | 1 |
| Vignetti, M | 1 |
| Piciocchi, A | 1 |
| Liso, V | 1 |
| Amadori, S | 1 |
| Leone, G | 1 |
| Scott, BL | 1 |
| Liu, B | 1 |
| Ohishi, K | 1 |
| Yamamura, K | 1 |
| Suzuki, K | 1 |
| Monma, F | 1 |
| Ino, K | 1 |
| Nishii, K | 1 |
| Masuya, M | 1 |
| Sekine, T | 1 |
| Heike, Y | 1 |
| Takaue, Y | 1 |
| Katayama, N | 1 |
| Goodyear, O | 1 |
| Agathanggelou, A | 1 |
| Novitzky-Basso, I | 1 |
| Siddique, S | 1 |
| McSkeane, T | 1 |
| Ryan, G | 1 |
| Vyas, P | 1 |
| Cavenagh, J | 1 |
| Stankovic, T | 1 |
| Moss, P | 1 |
| Craddock, C | 1 |
| Herrera, A | 1 |
| Labardini, J | 1 |
| González-Fierro, A | 1 |
| Trejo-Becerril, C | 1 |
| Taja-Chayeb, L | 1 |
| Pérez-Cárdenas, E | 1 |
| de la Cruz-Hernández, E | 1 |
| Arias-Bofill, D | 1 |
| Vidal, S | 1 |
| Cervera, E | 1 |
| Follo, MY | 1 |
| Mongiorgi, S | 1 |
| Clissa, C | 1 |
| Chiarini, F | 1 |
| Ramazzotti, G | 1 |
| Paolini, S | 1 |
| Martelli, AM | 1 |
| Cocco, L | 1 |
| Zhang, B | 1 |
| Li, CR | 1 |
| Zhou, JF | 1 |
| Wu, XQ | 1 |
| Chen, J | 1 |
| Yang, H | 3 |
| Fang, Z | 1 |
| Wei, Y | 1 |
| Hu, Y | 1 |
| Calin, GA | 1 |
| Raffoux, E | 1 |
| Cras, A | 1 |
| Recher, C | 1 |
| Boëlle, PY | 1 |
| de Labarthe, A | 1 |
| Turlure, P | 1 |
| Marolleau, JP | 1 |
| Reman, O | 1 |
| Gardin, C | 1 |
| Victor, M | 1 |
| Maury, S | 1 |
| Rousselot, P | 1 |
| Malfuson, JV | 1 |
| Maarek, O | 1 |
| Daniel, MT | 1 |
| Degos, L | 1 |
| Chomienne, C | 1 |
| Dombret, H | 1 |
| Wang, AH | 1 |
| Wei, L | 1 |
| Chen, L | 1 |
| Zhao, SQ | 1 |
| Wu, WL | 1 |
| Shen, ZX | 1 |
| Li, JM | 1 |
| Zhang, QY | 1 |
| Ge, GM | 1 |
| Yan, YP | 1 |
| Han, XL | 1 |
| Huang, Y | 1 |
| Wu, S | 1 |
| He, LS | 1 |
| So, CC | 1 |
| Wong, KF | 1 |
| Aivado, M | 1 |
| Bernhardt, A | 1 |
| Hildebrandt, B | 2 |
| Pilatrino, C | 1 |
| Cilloni, D | 1 |
| Messa, E | 1 |
| Morotti, A | 1 |
| Giugliano, E | 1 |
| Pautasso, M | 1 |
| Familiari, U | 1 |
| Cappia, S | 1 |
| Pelicci, PG | 1 |
| Lo Coco, F | 1 |
| Saglio, G | 1 |
| Guerrasio, A | 1 |
| Knipp, S | 1 |
| Fox, F | 1 |
| Steidl, C | 1 |
| Yee, KW | 1 |
| Giles, FJ | 1 |
| Sanchez-Gonzalez, B | 1 |
| Rosner, G | 1 |
| Verstovsek, S | 1 |
| Rytting, M | 1 |
| Wierda, WG | 2 |
| Koller, C | 1 |
| Xiao, L | 1 |
| Faderl, S | 2 |
| Estrov, Z | 2 |
| O'brien, S | 1 |
| Estey, E | 1 |
| Bueso-Ramos, C | 1 |
| Fiorentino, J | 1 |
| Soriano, AO | 1 |
| Giles, F | 1 |
| Ouzounian, S | 1 |
| Quezada, A | 1 |
| Estey, EH | 1 |
| Siitonen, T | 1 |
| Timonen, T | 1 |
| Juvonen, E | 1 |
| Terävä, V | 1 |
| Kutila, A | 1 |
| Honkanen, T | 1 |
| Mikkola, M | 1 |
| Hallman, H | 1 |
| Kauppila, M | 1 |
| Nyländen, P | 1 |
| Poikonen, E | 1 |
| Rauhala, A | 1 |
| Sinisalo, M | 1 |
| Suominen, M | 1 |
| Savolainen, ER | 1 |
| Koistinen, P | 1 |
| Zhao, HH | 2 |
| Dohner, K | 2 |
| Dohner, H | 1 |
| Allan, RW | 1 |
| Shah, P | 1 |
| Mato, A | 1 |
| Luger, SM | 1 |
| Fawcett, RG | 1 |
| Chybicka, A | 1 |
| Kołecki, P | 1 |
| Pietras, W | 1 |
| Bogusławska-Jaworska, J | 1 |
| Wójcik, D | 1 |
| Armata, J | 1 |
| Eliasińska, A | 1 |
| Kowalczyk, J | 1 |
| Jackowska, T | 1 |
| Klus, K | 1 |
| Matysiak, M | 1 |
| Krauze, A | 1 |
| Stefańska, K | 1 |
| Rokicka-Milewska, R | 1 |
| Wiśniewska-Slusarz, H | 1 |
| Ganick, DJ | 1 |
| Sunder, T | 1 |
| Finley, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736] | Early Phase 1 | 42 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial[NCT04482621] | Phase 2 | 33 participants (Actual) | Interventional | 2020-09-14 | Active, not recruiting | ||
| Randomized Phase II Trial Seeking the Most Promising Drug Association With Azacitidine- in Higher Risk Myelodysplastic Syndromes[NCT01342692] | Phase 2 | 320 participants (Anticipated) | Interventional | 2011-06-30 | Active, not recruiting | ||
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Phase I/II Study of 5-aza-2'-Deoxycytidine and Valproic Acid in Patients With Relapsed/Refractory Leukemia or Myelodysplastic Syndromes[NCT00075010] | Phase 1/Phase 2 | 54 participants (Actual) | Interventional | 2004-01-23 | Completed | ||
| Phase II Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia[NCT00326170] | Phase 2 | 34 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy[NCT01617226] | Phase 2 | 260 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical activity of combination defined as: Complete Response (CR), bone marrow with 5% or fewer blasts and peripheral blood count with an absolute neutrophil count of 10^9/L or more and platelet count of 100x10^9 or more; Complete response without platelets (CRp), a complete response except for a platelet count less than 100x10^9 and transfusion independent; and Bone Marrow (BM) Response, bone marrow blast of 5% or less but without meeting the peripheral blood count criteria for (CR) or (CRp). (NCT00326170)
Timeframe: Up to 12 cycles of treatment (28 day cycles)
| Intervention | Participants (Number) | ||
|---|---|---|---|
| CR | CRp | BM | |
| VPA + 5-aza + ATRA | 12 | 3 | 7 |
6 reviews available for valproic acid and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Efficacy and Safety of Valproic Acid in Myelodysplastic Syndrome and Acute Myeloid Leukemia; a Narrative Review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Myelodysplas | 2023 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progre | 2015 |
Demethylating agents in myeloid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; D | 2008 |
Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Enzyme Inhibitors; Humans; Leukemia, Myeloid, | 2008 |
Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature.
Topics: Cytogenetic Analysis; Female; Histone Deacetylase Inhibitors; Humans; Middle Aged; Myelodysplastic S | 2007 |
Current status of epigenetic treatment in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinic | 2008 |
15 trials available for valproic acid and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes T | 2015 |
Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Topics: Adult; Azacitidine; Bayes Theorem; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Myelodyspla | 2016 |
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Azacitidine; Cytochrome P-450 CYP2C19; DNA M | 2009 |
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Topics: Adult; Aged; Azacitidine; Cytogenetic Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DN | 2011 |
Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2011 |
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; | 2011 |
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Azacitidin | 2010 |
[The efficacy and safety of valproic acid in combination with low dose chemotherapy on intermediate and high-risk myelodysplastic syndrome].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Myel | 2011 |
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Male | 2004 |
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Topics: Acute Disease; Aged; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes | 2005 |
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell | 2005 |
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; Decit | 2006 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA M | 2007 |
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.
Topics: Acetylation; Aged; Aged, 80 and over; Calcitriol; Cheilitis; Chemical and Drug Induced Liver Injury; | 2007 |
[Treatment outcome for myelodysplastic syndromes (MDS) obtained by the Polish Children's Leukemia/Lymphoma Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool | 1998 |
20 other studies available for valproic acid and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes.
Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Idarubicin; Lenalidomide; Myelodysplastic S | 2022 |
Valproic Acid Induced Thrombocytopenia and Dysmegakaryopoiesis in a Pediatric Patient.
Topics: Aged; Anticonvulsants; Bone Marrow; Child; Female; Humans; Myelodysplastic Syndromes; Thrombocytopen | 2022 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Tr | 2017 |
Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; D | 2015 |
[Sodium valproate synergizes adriamycin to inhibit proliferation and induce apoptosis in myelodysplastic syndrome cell line].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Myelodysplasti | 2008 |
Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Ger | 2009 |
Is survival enough for myelodysplastic syndromes?
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Ger | 2009 |
Clinical roundtable monograph. Combination therapies for MDS.
Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic | 2009 |
A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis.
Topics: Antigens, CD34; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; GABA Agents; GATA1 Transc | 2010 |
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Aged; Aged, 80 and over; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Comb | 2010 |
[Effect of sodium valproate on human myelodysplastic syndrome cell line SKM-1 and its mechanism].
Topics: Apoptosis; Calcium-Binding Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tu | 2010 |
Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Ce | 2011 |
Valproate-associated dysmyelopoiesis in elderly patients.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Valproic Ac | 2002 |
Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; D | 2005 |
[Apoptosis of human myelodysplastic syndrome cell Line MUTZ-1 induced by sodium valproate].
Topics: Apoptosis; Cell Cycle; Cell Line; Dose-Response Relationship, Drug; Humans; Myelodysplastic Syndrome | 2007 |
[Effects of sodium valproate on proliferation and apoptosis of human myelodysplastic syndromes cell line MUTZ-1].
Topics: Apoptosis; Cell Cycle; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dose-Re | 2007 |
Valproic acid for the treatment of myeloid malignancies.
Topics: Adult; Anticonvulsants; Female; Humans; Myelodysplastic Syndromes; Pilot Projects; Remission Inducti | 2008 |
Dose-related thrombocytopenia and macrocytic anemia associated with valproate use in bipolar disorder.
Topics: Anemia, Macrocytic; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Middle Aged; Myelod | 1997 |
Severe hematologic toxicity of valproic acid. A report of four patients.
Topics: Adolescent; Bone Marrow; Child, Preschool; Erythroid Precursor Cells; Female; Humans; Myelodysplasti | 1990 |